More Company News

Allergy Therapeutics

Completion of treatment phase in G309 study
06 May 2021Read More

Allergy Therapeutics

Interim H121 results
03 Mar 2021Read More

Allergy Therapeutics

H121 trading update and notice of results
13 Jan 2021Read More

Allergy Therapeutics

Initiation of peanut allergy biomarker study
05 Jan 2021Read More

Allergy Therapeutics

Initiation of Grass MATA MPL exploratory study
26 Oct 2020Read More

Allergy Therapeutics

FY20 preliminary results
23 Sep 2020Read More

Allergy Therapeutics

Allergy Therapeutics secures VLP technology platform
03 Sep 2020Read More

Allergy Therapeutics

FY20 trading update
15 Jul 2020Read More

Allergy Therapeutics

Invalidation of Birch MATA MPL Phase III results
09 Jul 2020Read More

Allergy Therapeutics

Trading update
24 Jun 2020Read More

1 2
Return to Allergy Therapeutics
© 2019-21 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).